View Item 

Show simple item record

Safety and Efficacy of Oxcarbazepine: Results of Randomized, Double‐Blind Trials

dc.contributor.authorBeydoun, Ahmad A.en_US
dc.date.accessioned2012-03-16T15:58:36Z
dc.date.available2012-03-16T15:58:36Z
dc.date.issued2000-08en_US
dc.identifier.citationBeydoun, Ahmad (2000). "Safety and Efficacy of Oxcarbazepine: Results of Randomized, Double‐Blind Trials." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 20(8P2): 152S-158S. <http://hdl.handle.net/2027.42/90287>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90287
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.titleSafety and Efficacy of Oxcarbazepine: Results of Randomized, Double‐Blind Trialsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan Medical Center, Ann Arbor, Michiganen_US
dc.identifier.pmid10937814en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90287/1/phco.20.12.152S.35254.pdf
dc.identifier.doi10.1592/phco.20.12.152S.35254en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceMogensen P.H., Jorgensen L., Boas J., et al. Effects of dextropropoxyphene on the steady‐state kinetics of oxcarbazepine and its metabolites. Acta Neurol Scand 1992; 85: 14 – 7.en_US
dc.identifier.citedreferenceChriste W., Kramer G., Vigonius U., et al. A double‐blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. 1997; 26: 451 – 60.en_US
dc.identifier.citedreferenceDam M., Ekberg R., Loyning Y., Waltimo O., Jakobsen K.. A double‐blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 1989; 3: 70 – 6.en_US
dc.identifier.citedreferenceSachdeo R.C., Edwards K., Hasegawa H., et al. Safety and efficacy of oxcarbazepine 1200 mg/day in patients with recent‐onset partial epilepsy [abstr]. Neurology 1999; 52 ( suppl 2 ): A391.en_US
dc.identifier.citedreferenceSchachter S.C., Vazquez B., Fisher R.S., et al. Oxcarbazepine: double‐blind, randomized, placebo‐control, monotherapy trial for partial seizures. Neurology 1999; 52: 732 – 7.en_US
dc.identifier.citedreferenceBeydoun A., Sachdeo R.C., Rosenfeld W.E., et al. Oxcarbazepine monotherapy for partial‐onset seizures: a multicenter, double‐blind, clinical trial. Neurology 2000; 54: 2245 – 51.en_US
dc.identifier.citedreferenceSachdeo R., Beydoun A., Schachter S., et al. Safety and efficacy of oxcarbazepine monotherapy [abstr]. Neurology 1998; 50: A200.en_US
dc.identifier.citedreferenceKramer G., Tettenborn B., Jensen P.K., Menge G.P., Stoll K.D.. Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia 1992; 33: 1145 – 8.en_US
dc.identifier.citedreferenceKramer G., Tettenborn B., Flesch G.. Oxcarbazepine‐verapamil drug interaction in healthy volunteers. Epilepsia 1991; 32 ( suppl 1 ): 70 – 1.en_US
dc.identifier.citedreferenceKeranen T., Jolkkonen J., Klosterskov‐Jensen P., Menge G.P.. Oxcarbazepine does not interact with cimetidine in healthy volunteers. Acta Neurol Scand 1992; 85: 239 – 42.en_US
dc.identifier.citedreferenceKeranen T., Jolkkonen J., Jensen P.K., Menge G.P., Andersson P.. Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand 1992; 86: 120 – 3.en_US
dc.identifier.citedreferenceJensen P. Klosterskov, Saano V., Haring P., Svenstrup B., Menge G.P.. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 1992; 33: 1149 – 52.en_US
dc.identifier.citedreferenceReinikainen K.J., Keranen T., Halonen T., Komulainen H., Riekkinen P.J.. Comparison of oxcarbazepine and carbamazepine: a double‐blind study. Epilepsy Res. 1987; 1: 284 – 9.en_US
dc.identifier.citedreferenceIsojarvi J.I., Pakarinen A.J., Rautio A., Pelkonen O., Myllyla V.V.. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 1994; 35: 1217 – 20.en_US
dc.identifier.citedreferenceFaigle J.W., Menge G.P.. Metabolic characteristics of oxcarbazepine (Trileptal®) and their beneficial implications for enzyme induction and drug interactions. Behav Neurol 1990; 3 ( suppl ): S21 – 30.en_US
dc.identifier.citedreferenceSchacter S.C.. Oxcarbazepine: current status and clinical applications. Exp Opin Invest Drugs 1999; 8: 1 – 10.en_US
dc.identifier.citedreferenceNovartis Pharmaceuticals Corporation Trileptal (oxcarbazepine) package insert. East Hanover, NJ; 2000.en_US
dc.identifier.citedreferenceDickinson R.G., Hooper W.D., Dunstan P.R., Eadie M.J.. First dose and steady‐state pharmacokinetics of oxcarbazepine and its 10‐hydroxy metabolite. Eur J Clin Pharmacol 1989; 37: 69 – 74.en_US
dc.identifier.citedreferenceLloyd P., Flesch G., Dieterle W.. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994; 35: S10 – 3.en_US
dc.identifier.citedreferencePatsalos P.N., Stephenson T.J., Krishna S., Elyas A.A., Lascelles P.T., Wiles C.M.. Side‐effects induced by carbamazepine‐10, 11‐epoxide [letter]. Lancet 1985; 2: 1432.en_US
dc.identifier.citedreferenceWamil A.W., Schmutz M., Portet C., Feldmann K.F., McLean M.J.. Effects of oxcarbazepine and 10‐hydroxycarbamazepine on action potential firing and generalized seizures. Eur J Pharmacol 1994; 271: 301 – 8.en_US
dc.identifier.citedreferenceBarcs G., Walker E.B., Elger C.E., et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia, in press.en_US
dc.identifier.citedreferenceGlauser T.A., Nigro M., Sachdeo R., et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology 2000; 54: 2237 – 44.en_US
dc.identifier.citedreferenceBill P.A., Vigonius U., Pohlmann H., et al. A double‐blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. 1997; 27: 195 – 204.en_US
dc.identifier.citedreferenceGuerreiro M.M., Vigonius U., Pohlmann H., et al. A double—blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. 1997; 27: 205 – 13.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.20.12.152S.35254.pdf
Size:
48.04KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.